Oncology

Duration of sleep and snoring may play a role in survival outcomes.

Early palliative care reduces costs more than traditional treatment standards.

Promacta is the first and only oral thrombopoietin-receptor agonist that increases platelet production.

Increasing number of urology practices working with specialty pharmacies.

Men with AR-V7 variant more likely to be resistant to hormone drugs.

Drug is being evaluated for the treatment of patients who received at least 3 prior lines of therapy.

Glioblastoma treatment with surgical resection may benefit patients with worst prognoses.

Undertreated side effects in treatment of some colon and stomach cancers need to be addressed.

Recently published data from a survey of commercial health plans reveal the latest trends and emerging strategies in oncology management.

Proposed regulations call for the use of closed-system transfer devices by health care professionals who handle hazardous drugs.

Costs grow for people with oral cavity and pharyngeal cancers based on demographics, co-existing illnesses, and treatment selection.

Biological mechanisms of breast milk may have preventative effect.

Mobile adherence apps are a great boon to patients who face the responsibility of taking oral chemotherapy drugs as directed without in-person supervision by clinicians.

Pharmaceutical companies and clinical oncology teams are collaborating to harness large sets of patient data, paving the way for more informed and individualized decision-making about treatments.

As oncology spending rises, insurers and manufacturers are looking to specialty pharmacy programs to maximize the effectiveness of cancer therapies.

There are several key factors a specialty pharmacy must consider when deciding whether to participate in a limited distribution network.

New drug approvals include therapies for patients with breast cancer, thyroid cancer, neuroblastoma, and multiple myeloma.

Cost containment of medications for the treatment of cancer is an area of increasing concern for specialty pharmacy stakeholders.

Nivolumab extends life by 3.2 months compared with chemotherapy.

Nivolumab has increased the survival rate in patients with low grade adverse events.

Extracts show strong activity in treatment of cervical cancer cells.

Combination therapy with AKT inhibitors shows promise.